ABEO
Price
$5.75
Change
-$0.15 (-2.54%)
Updated
Jun 27 closing price
Capitalization
294.15M
50 days until earnings call
GOSS
Price
$1.25
Change
-$0.05 (-3.85%)
Updated
Jun 27 closing price
Capitalization
281.85M
44 days until earnings call
Interact to see
Advertisement

ABEO vs GOSS

Header iconABEO vs GOSS Comparison
Open Charts ABEO vs GOSSBanner chart's image
Abeona Therapeutics
Price$5.75
Change-$0.15 (-2.54%)
Volume$7.02M
Capitalization294.15M
Gossamer Bio
Price$1.25
Change-$0.05 (-3.85%)
Volume$26.07M
Capitalization281.85M
ABEO vs GOSS Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. GOSS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and GOSS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ABEO: $5.75 vs. GOSS: $1.25)
Brand notoriety: ABEO and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 330% vs. GOSS: 1262%
Market capitalization -- ABEO: $294.15M vs. GOSS: $281.85M
ABEO [@Biotechnology] is valued at $294.15M. GOSS’s [@Biotechnology] market capitalization is $281.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABEO and GOSS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 1 TA indicator(s) are bullish while GOSS’s TA Score has 2 bullish TA indicator(s).

  • ABEO’s TA Score: 1 bullish, 7 bearish.
  • GOSS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -2.38% price change this week, while GOSS (@Biotechnology) price change was -13.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

GOSS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($294M) and GOSS($282M) have the same market capitalization . GOSS YTD gains are higher at: 38.183 vs. ABEO (3.232). GOSS (-35.7M) and ABEO (-36.93M) have comparable annual earnings (EBITDA) . GOSS has more cash in the bank: 258M vs. ABEO (84.2M). ABEO has less debt than GOSS: ABEO (24M) vs GOSS (203M). GOSS has higher revenues than ABEO: GOSS (125M) vs ABEO (0).
ABEOGOSSABEO / GOSS
Capitalization294M282M104%
EBITDA-36.93M-35.7M103%
Gain YTD3.23238.1838%
P/E RatioN/AN/A-
Revenue0125M-
Total Cash84.2M258M33%
Total Debt24M203M12%
FUNDAMENTALS RATINGS
ABEO vs GOSS: Fundamental Ratings
ABEO
GOSS
OUTLOOK RATING
1..100
6353
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4942
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (59) in the Pharmaceuticals Generic industry is in the same range as GOSS (60) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to GOSS’s over the last 12 months.

ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to GOSS’s over the last 12 months.

ABEO's SMR Rating (100) in the Pharmaceuticals Generic industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as ABEO (49) in the Pharmaceuticals Generic industry. This means that GOSS’s stock grew similarly to ABEO’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that GOSS’s stock grew similarly to ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOGOSS
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EULIF0.05N/A
+6.38%
EUROPEAN LITHIUM LTD.
FSUGY20.110.44
+2.24%
FORTESCUE LTD.
DSRLF107.68N/A
N/A
Diasorin S.R.L.
NURPF8.81N/A
N/A
Neuren Pharmaceuticals Ltd.
PLSH0.04N/A
N/A
PANACEA LIFE SCIENCES HLDGS INC.

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ERAS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
-2.54%
ERAS - ABEO
46%
Loosely correlated
N/A
ZYME - ABEO
46%
Loosely correlated
+0.81%
IPSC - ABEO
45%
Loosely correlated
-5.74%
DAWN - ABEO
45%
Loosely correlated
-0.15%
CRNX - ABEO
45%
Loosely correlated
-0.10%
More